did nice conclude cbt beats antidepressants for milder depression, with fewer side effects?
“nice, which is the British organization that passes on what treatments the National Health Service will support and which ones are uh sufficiently evidence-based, um has come to that same conclusion.”
a guest, a historian of psychiatry said on Lex Fridman Podcast, 2026-09-21, at 09:51. hear it in context → the speaker cited: NICE (British National Institute for Health and Care Excellence).
first, the part that holds
this part is true: NICE's 2022 adult depression guideline moved antidepressants down for less severe depression. it says they should not routinely be offered first-line unless that is the person's preference, and it places CBT and behavioural activation among its top-ranked first-line options.
what we found when we went and looked
NICE's 2022 guideline (NG222) gives 11 first-line options for less severe depression, ordered by clinical effectiveness, cost-effectiveness and how easy they are to deliver. CBT and behavioural activation are in the top four. the network meta-analysis NICE paid for (142 trials, 16,829 people in the less severe group) found group CBT effective against usual care (SMD −1.01, 95% CrI −1.76 to −0.06). individual CBT was borderline, and antidepressants showed no evidence of effect against usual care or pill placebo. that is not the same as NICE concluding that "CBT works better than antidepressants". the ranking also includes cost and ease of delivery, and the analysis itself says no head-to-head comparison between the two classes was available. on "fewer side effects", the records we read show antidepressants causing more dropouts due to side effects than pill placebo, in more severe depression, not compared with CBT in milder depression.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| NICE has concluded that CBT works better than antidepressant drugs for milder forms of depression | overstated | NICE ranks CBT above SSRIs for less severe depression, but the order combines clinical effectiveness, cost-effectiveness and ease of delivery, and group formats rank higher partly because they cost less. the NICE-funded network meta-analysis found group CBT effective against usual care, individual CBT borderline, and antidepressants with no evidence of effect against usual care or pill placebo in less severe depression. it also says no direct comparison of CBT against antidepressants was available within its severity groups. the direction is right. 'works better' is a firmer comparison than the evidence or the ranking states. [1][2] |
| NICE concluded CBT has fewer side effects than antidepressants for milder depression | unverifiable | in the records we could read, the side-effect finding is that every antidepressant class assessed had a higher risk of discontinuation due to side effects than pill placebo, and the analysis states this for more severe depression. we found no NICE statement comparing side effects of CBT and antidepressants in less severe depression in the material we fetched. the guideline's own tables were blocked to our fetch. [1] |
| NICE advises against routinely offering antidepressants as first-line treatment for less severe depression | confirmed | a 2025 peer-reviewed paper quotes NICE's advice that antidepressants should not be routinely offered first-line for less severe depression 'unless that is the person's preference'. the paper argues that this preference clause should be removed. [3] |
| in NICE's ordered list for less severe depression, CBT sits near the top and SSRIs lower | confirmed | a 2023 guideline comparison describes 11 ranked first-line treatments sequenced 'according to clinical and cost-effectiveness alongside consideration of implementation factors'. CBT and behavioural activation are in the top four. SSRIs sit ahead of short-term psychodynamic psychotherapy, which is ranked last. [2] |
both directions
for the speaker: NICE's recommendation not to routinely offer antidepressants first-line for less severe depression is in the record. so is its ranking of CBT and behavioural activation in the top four of its 11 first-line options. the evidence base NICE commissioned found group CBT effective against usual care in less severe depression and found no evidence of effect for antidepressants against either usual care or pill placebo. the same analysis found antidepressants caused more dropouts due to side effects than pill placebo, which fits the side-effect clause in direction.
against: NICE did not phrase this as CBT "working better" than antidepressants. its order is a blend of clinical effectiveness, cost-effectiveness and ease of delivery, and one comparison paper says group therapies rank higher "presumably largely because of cost savings". individual CBT was borderline against usual care in the NICE analysis, and that analysis had no direct CBT-versus-antidepressant comparison within its severity groups. SSRIs are still on NICE's list of first-line options for less severe depression, available when that is the person's informed preference. the side-effect finding we could read was against pill placebo in more severe depression, not against CBT in milder depression. a 2022 editorial from guideline authors in another country argues the two sets of guidelines recommend the same interventions in largely the same order, and notes how little evidence exists for many key clinical questions.
what this cannot say
nice.org.uk, bmj.com and the NCBI Bookshelf copy of the guideline all blocked our automated fetches. so we did not read NG222's recommendation text or its options table directly, and we rely on the NICE-funded network meta-analysis and on peer-reviewed papers that quote or describe the guideline. NICE's table may say more about side effects than we could confirm, and that is why the side-effect clause is unverifiable rather than false. network meta-analysis estimates against 'treatment as usual' depend on what usual care meant in each trial. standardised effect sizes say nothing about how one person will respond. this check is about what NICE concluded, not advice on any individual's treatment.
sources, each one fetched and read
- Mavranezouli I, et al. A systematic review and network meta-analysis of psychological, psychosocial, pharmacological, physical and combined treatments for adults with a new episode of depression. eClinicalMedicine, 2024. doi:10.1016/j.eclinm.2024.102780 (funded by NICE) What we read there: less severe network: 142 RCTs, 16,829 participants. group CBT vs treatment as usual SMD −1.01 (95% CrI −1.76; −0.06). 'Antidepressants did not show evidence of effect compared with either TAU or pill placebo.' in more severe depression 'All assessed antidepressant classes showed higher risk of discontinuation due to side effects compared with pill placebo.' notes the work informed the updated NICE guideline on depression in adults. Fetched 2026-10-19 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC11377144
- Malhi GS, et al. Positioning of psychodynamic psychotherapy in the treatment of depression: a comparison of the RANZCP 2020 and NICE 2022 guidelines. Australasian Psychiatry, 2023. doi:10.1177/10398562231159329 What we read there: NICE ranks 11 first-line treatments for less severe depression, 'sequenced according to clinical and cost-effectiveness alongside consideration of implementation factors'. CBT and behavioural activation are in the top four, group therapies rank higher 'presumably largely because of cost savings', and SSRIs are positioned ahead of short-term psychodynamic psychotherapy, which is ranked last. Fetched 2026-10-19 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC10251463/
- Davies J, Read J. Should antidepressants be prescribed simply if it is the patient's preference? Why NICE guidelines must be revised. British Journal of General Practice, 2025. doi:10.3399/BJGP.2025.0596 What we read there: NICE advises antidepressants should not be routinely offered as first-line treatment for less severe depression 'unless that is the person's preference'. the authors argue the preference clause should be removed. Fetched 2026-10-19 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC13044191/
- Malhi GS, et al. The management of depression: the evidence speaks for itself. British Journal of Psychiatry, 2022;222(3):97-99. doi:10.1192/bjp.2022.133 What we read there: 'NG222 sequences treatment options' separately for less severe and more severe depression. it 'factored both the accessibility and the ability to implement treatments into its considerations'. the authors note 'the paucity of empirical evidence to support recommendations for many key clinical questions'. Fetched 2026-10-19 (HTTP 200). https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/management-of-depression-the-evidence-speaks-for-itself/D0FCC3A45F1CD20635A3ABB7072E8D70
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam